Table 2.
Ongoing neoadjuvant phase III clinical trials with chemotherapy and immunotherapy. pCR: pathological complete response; EFS: event-free survival; OS: overall survival.
| Trial | Stage | Neoadjuvant Treatment | Adjuvant Treatment | Primary Endpoint | Status |
|---|---|---|---|---|---|
|
NCT02998528 Checkmate816 [41,42] |
IIB–IIIA | Platinum + vinorelbine/pemetrexed/gemcitabine/docetaxel/paclitaxel + nivolumab vs. Platinum + vinorelbine/pemetrexed/gemcitabine/docetaxel/paclitaxel |
NA | pCR; EFS | Active, not recruiting |
|
NCT04025879 Checkmate77T [43] |
IIA–IIIB (T3N2) | Platinum + pemetrexed/docetaxel/paclitaxel + nivolumab vs. Platinum + pemetrexed/docetaxel/paclitaxel |
Nivolumab for 1year vs. placebo |
EFS | Recruiting |
|
NCT03456063 Impower030 [44] |
II–IIIA–IIIB (T3N2) | Platinum + pemetrexed/gemcitabine/nab-paclitaxel + atezolizumab vs. Platinum + pemetrexed/gemcitabine/nab-paclitaxel |
Atezolizumab for 48weeks vs. placebo |
EFS | Active, not recruiting |
|
NCT03425643 KEYNOTE671 [45] |
IIA–IIIA–IIIB (N2) | Cisplatin + pemetrexed/gemcitabine + pembrolizumab vs. Cisplatin + pemetrexed/gemcitabine |
Pembrolizumab for 39weeks vs. placebo |
EFS; OS | Recruiting |
|
NCT03800134 AEGEAN [46] |
IIA–IIIA -IIIB(N2) | Platinum + pemetrexed/gemcitabine/paclitaxel + durvalumab vs. Platinum + pemetrexed/gemcitabine/paclitaxel |
Durvalumab for 1 year vs. placebo |
pCR; EFS | Recruiting |